<DOC>
	<DOC>NCT01283724</DOC>
	<brief_summary>A clinical trial which was designed to demonstrate the safety and efficacy of Visanne (approved in endometriosis for adults) in the adolescent population.</brief_summary>
	<brief_title>Visanne Study to Assess Safety in Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>Female adolescents after menarche (12 less than 18 years of age) at screening. For Finland: Adolescents aged 12 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy. Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions: Clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal antiinflammatory drugs and/or oral contraceptives Any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent) Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration postsurgery) Threshold for endometriosisassociated pelvic pain (EAPP) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks Absence of endometriosis at laparoscopy Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months) Clinically established need for primary surgical treatment of endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>DEXA</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Post-menarche</keyword>
</DOC>